FDA折点更新至自动化药敏试验系统许可的公开监管时间间隔:2017-2026年纵向数据库研究
本研究测量了2017年1月1日至2026年8月23日FDA药物特异性折点行动至MicroScan、VITEK 2/VITEK 2 Compact和BD Phoenix的510(k)许可之间的公开可见间隔。中位总间隔为22.3个月(IQR 9.1-42.0),中位提交间隔为13.3个月,中位审评间隔为6.9个月。
要点
- FDA折点更新至自动化药敏系统510(k)许可的中位总间隔为22.3个月。
- 提交前间隔(中位13.3个月)长于FDA审评间隔(中位6.9个月)。
- 12个折点事件未识别到合格公开链接,但不能据此认定标签过时。
核心结论
- 公开510(k)记录显示折点至许可间隔异质,提交前成分长于审评成分。
- 建立带日期、机器可读的折点相关标签变更登记库可提高透明度。
研究设计与样本
- 纵向数据库研究,链接2017年1月1日至2026年8月23日FDA药物特异性折点行动与MicroScan、VITEK 2/VITEK 2 Compact、BD Phoenix的510(k)决策摘要。
主要发现
- 中位总间隔22.3个月(IQR 9.1-42.0;范围0.1-59.7)。
- 中位提交间隔13.3个月(IQR 5.7-32.8)。
- 独特许可的中位审评间隔6.9个月(IQR 3.1-7.7)。
- 3份提交在相应折点行动之前收到。
- 12个事件未识别到合格公开链接,但不能确立标签过时,因为已许可的变更方案可能允许无需另一次510(k)的更新。
临床怎么用
- 检验科可参考公开510(k)记录评估自动化药敏系统折点更新滞后情况。
- 关注折点相关标签变更的透明度,包括无需新510(k)的更新。
局限性
- 12个事件未识别到合格公开链接,但不能据此确立标签过时。
- 已许可的变更方案可能允许无需另一次510(k)的更新,公开记录可能未反映此类更新。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Updated antimicrobial susceptibility testing (AST) breakpoints require implementation in laboratory systems, but the timing of device updates across revisions has not been quantified. We measured publicly visible intervals from US Food and Drug Administration (FDA) breakpoint actions to clearances for established automated AST platforms. METHODS: Drug-specific FDA breakpoint actions from January 1, 2017, through August 23, 2026, were linked to 510(k) decision summaries for MicroScan, VITEK 2/VITEK 2 Compact, and BD Phoenix when the public record supported the drug, organism group, platform, and updated breakpoint relationship. Total lag was decomposed into breakpoint-to-receipt submission lag and receipt-to-decision FDA review interval. RESULTS: Eighty-nine FDA notice rows yielded 22 eligible breakpoint events. Among 103 screened decision summaries, 13 clearances supported 18 links; 16 primary links involving 11 unique clearances and 10 events met prespecified criteria. Median total lag was 22.3 months (interquartile range, 9.1-42.0; range, 0.1-59.7), median submission lag was 13.3 months (interquartile range, 5.7-32.8), and the median review interval among unique clearances was 6.9 months (interquartile range, 3.1-7.7). Three submissions were received before the corresponding breakpoint action. No qualifying public link was identified for 12 events, but this cannot establish outdated labeling because cleared change protocols may permit updates without another 510(k). CONCLUSIONS: Public 510(k) records show heterogeneous breakpoint-to-clearance intervals, with a longer prereceipt than review component. A dated, machine-readable registry of breakpoint-related labeling changes would improve transparency, including for updates made without a new 510(k).
引用
- Li Z, He X. Publicly visible regulatory timing from US Food and Drug Administration breakpoint updates to automated antimicrobial susceptibility test clearances: a longitudinal database study, 2017-2026. Am J Clin Pathol. 2026. PMID: 42912744. doi:10.1093/ajcp/aqag112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。